TScan Therapeutics (TCRX)
(Delayed Data from NSDQ)
$7.32 USD
+0.03 (0.41%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $7.30 -0.02 (-0.27%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Price, Consensus and EPS Surprise
TCRX 7.32 +0.03(0.41%)
Will TCRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TCRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TCRX
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
TCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates
Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar?
Other News for TCRX
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
Unveiling 4 Analyst Insights On TScan Therapeutics
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
Simplify Propel Opportunities ETF: Healthcare Likely To Rise Again In FY24 And Beyond